Shahla Abdollahi
About Shahla Abdollahi
Shahla Abdollahi is a Senior Principal Scientist at Bristol Myers Squibb in Cambridge, Massachusetts, with extensive experience in autoimmune and inflammatory disease research.
Current Role at Bristol Myers Squibb
Shahla Abdollahi is a Senior Principal Scientist at Bristol Myers Squibb, currently based in Cambridge, Massachusetts. In her role, she leads the design, execution, and oversight of both in vitro and in vivo studies. Her work focuses primarily on autoimmune and inflammatory diseases, utilizing a variety of in vivo efficacy models including those for arthritis, colitis, and periodontitis.
Previous Positions at Bristol Myers Squibb
Before her current role, Shahla Abdollahi has held multiple positions at Bristol Myers Squibb in Cambridge, Massachusetts. She served as a Principal Scientist for 10 months in 2021 and as a Senior Scientist from 2019 to 2021. These roles involved significant research and development activities, particularly in the fields of autoimmune and inflammatory diseases.
Experience at Celgene
Shahla Abdollahi worked at Celgene as a Senior Scientist from 2018 to 2021 in Cambridge, Massachusetts. In this role, she was responsible for initiating and executing several collaborative multidisciplinary projects across various functional groups, applying her expertise in autoimmune and inflammatory disease models.
Academic and Research Background
Shahla Abdollahi's academic journey includes a PhD in Rheumatology and Immunology from Radboud University Medical Centre Nijmegen, which she completed in 2009. She also holds an MSc in Biomedical Sciences from the same institution. Her postdoctoral research was conducted at Columbia University, New York, focusing on Microbiology and Immunology. She has held academic positions as an Assistant Professor at New York University School of Medicine and a Postdoctoral Researcher at Columbia University Medical Center/NewYork-Presbyterian Hospital.
Scientific Contributions and Publications
Shahla Abdollahi has authored over 40 peer-reviewed publications and has been a speaker at more than 30 international conferences. Her research contributions have significantly advanced the understanding of autoimmune and inflammatory diseases. Her work has been recognized for its impact on both academic and clinical research in these fields.